Novel and emerging therapies offer new hope for patients with inflammatory bowel disease

Reviewed by Lily Ramsey, LLMNov 7 2023 In recent decades, there have been significant advances in the understanding of IBD pathophysiology and the development of new treatments.

The International Organisation for the Study of Inflammatory Bowel Diseases developed the Selecting Therapeutic Targets in Inflammatory Bowel Disease programs, which recommend specific treatment goals for UC and CD in children and adults. These goals include clinical response and remission, endoscopic healing, normalization of C-reactive protein/erythrocyte sedimentation rate and fecal calprotectin, prevention of disability, restoration of quality of life, and normal growth in children.

The current mainstay treatments for IBD include immunomodulators, biologics agents being the most commonly used), and other monoclonal antibodies such as anti-integrins and anti-interleukins . However, primary and secondary loss of response to these therapies is a major recurring issue, with often diminishing returns in terms of efficacy for the next line of therapies prescribed.

Recently, there has been an influx of new and emerging medications entering the market that are showing promising efficacy results in patients with moderate-to-severe IBD who have previously failed to respond to multiple drugs. These novel and emerging therapies include: Related Stories These novel and emerging therapies offer new hope for patients with moderate-to-severe IBD who have previously failed to respond to multiple drugs. More research is needed to confirm their long-term safety and efficacy, but they have the potential to revolutionize the treatment of IBD.Journal reference:Kumar, A., et al. Horizon scanning: new and future therapies in the management of inflammatory bowel disease. eGastroenterology. doi.org/10.1136/egastro-2023-100012.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Investigating new and future therapies for managing inflammatory bowel diseaseUlcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases (IBD) that affect the gastrointestinal tract. In recent decades, there have been significant advances in the understanding of IBD pathophysiology and the development of new treatments.
Source: medical_xpress - 🏆 101. / 51 Read more »

Inflammatory bowel disease increases risk for later arrhythmiasPatients with inflammatory bowel disease (IBD) overall, as well as Crohn disease (CD) and ulcerative colitis (UC) individually, have an increased risk for developing later arrhythmias, according to a study published online Oct. 19 in PLOS Medicine.
Source: medical_xpress - 🏆 101. / 51 Read more »

Novel urine-based test offers new hope for bladder cancer patientsBladder cancer, notorious for being one of the most costly malignancies to manage, often results in patient discomfort and frequent invasive and expensive procedures.
Source: medical_xpress - 🏆 101. / 51 Read more »

Research team proposes novel AI-enabled gastrointestinal diagnostic system inspired by rat whiskersGastrointestinal (GI) diseases, whose symptoms can be varied and painful, may lead to serious health problems, and present a formidable health challenge throughout the world. For these diseases, early diagnosis and intervention are crucial for treatment success and mortality risk reduction.
Source: medical_xpress - 🏆 101. / 51 Read more »

Body changes detected up to eight years before inflammatory bowel disease diagnosisResearchers at the Francis Crick Institute and Aalborg University in Copenhagen have shown that changes can be detected in blood tests up to eight years before a diagnosis of Crohn's disease and up to three years before a diagnosis of ulcerative colitis.
Source: medical_xpress - 🏆 101. / 51 Read more »